Skip to main content
. 2020 Sep 30;12(10):3001. doi: 10.3390/nu12103001

Figure 2.

Figure 2

Human disorders of phosphate homeostasis caused by transporters of inorganic phosphate (Pi). Compounds that inhibit Pi transport are denoted in red, while compounds that stimulate Pi transport are denoted in green. 1 These compounds may affect their respective Pi transporters in tissues other than the ones that the compounds are listed under. For example, NPT2A inhibitors may also affect Pi transport in the bone. Additionally, tenapanor is not a direct inhibitor of Pi transport through NPT2B. 2 XPR1 small peptide inhibitors were only reported in in vitro studies. Question mark indicates unknown. FGF23, fibroblast growth factor 23. BMD, bone mineral density. NAD, nicotinamide adenine dinucleotide. NPT1, sodium-dependent phosphate transport protein 1. NPT2A, sodium-dependent phosphate transport protein 2A. NPT2B, sodium-dependent phosphate transport protein 2B. NPT2C, sodium-dependent phosphate transport protein 2C. PFA, phosphonoformic acid. PIT1, type III sodium-dependent Pi transporter 1. PIT2, type III sodium-dependent Pi transporter 2. PIC, (SLC25A3, solute carrier family 25 member 3). XPR1, xenotropic and polytropic retrovirus receptor 1. XRBD, soluble ligand that can bind XPR1. Adapted from [46].